Treatment with NS3623, a novel Cl-conductance blocker, ameliorates erythrocyte dehydration in transgenic SAD mice: a possible new therapeutic approach for sickle cell disease.
about
Drugs for preventing red blood cell dehydration in people with sickle cell diseaseMagnesium for treating sickle cell diseaseZinc supplements for treating thalassaemia and sickle cell diseaseDrugs for preventing red blood cell dehydration in people with sickle cell diseaseZinc supplements for treating thalassaemia and sickle cell diseaseDrugs for preventing red blood cell dehydration in people with sickle cell diseaseIdentification of a Small Molecule that Increases Hemoglobin Oxygen Affinity and Reduces SS Erythrocyte SicklingMagnesium for treating sickle cell diseaseActivation of human ether-a-go-go related gene (hERG) potassium channels by small moleculesPTPepsilon has a critical role in signaling transduction pathways and phosphoprotein network topology in red cells.Newer aspects of the pathophysiology of sickle cell disease vaso-occlusion.Ion transport pathology in the mechanism of sickle cell dehydration.Channel or transporter? The CLC saga continues.Pharmacological inhibition of calpain-1 prevents red cell dehydration and reduces Gardos channel activity in a mouse model of sickle cell disease.Hyperthermia, dehydration, and osmotic stress: unconventional sources of exercise-induced reactive oxygen species.Reduced DIDS-sensitive chloride conductance in Ae1-/- mouse erythrocytes.The effect of deoxygenation on whole-cell conductance of red blood cells from healthy individuals and patients with sickle cell disease.Pharmacological investigation of the role of ion channels in salivary secretion.Oxidative stress effects on erythrocytes determined by FT-IR spectrometry.Regulation of Kv4.3 and hERG potassium channels by KChIP2 isoforms and DPP6 and response to the dual K+ channel activator NS3623.
P2860
Q24186046-0E698F60-5118-4D1C-899B-A85E0C6AEEBEQ24193246-368A295F-678D-4D0B-A590-B76D00A0B8A2Q24201778-DCEC4465-A315-4909-9577-6E8E17F8905DQ24202032-FC37AB8F-2285-4511-A047-1A9113D5107BQ24235513-F22896A9-AE15-4D59-ABAD-C2808D0926E5Q24240777-77A47888-BF1E-48FA-96D8-20BAEEE8BFD5Q27684817-D5A0D9A4-38E7-4FE3-A7E2-404EB84F13E8Q29994630-E7951466-F7AE-455C-9279-4C6D6BEE4837Q33859184-A5E1F878-84F0-4AED-8DED-1E8B30DA2EBDQ34433518-C7319876-77D4-4A84-8E78-AA904985D896Q34941213-504F926D-1ECA-4DF0-BEB6-4B327EE5CF23Q35993299-93C244E9-005C-4A1E-996A-3631369F297CQ36265267-5EB9C46D-3A9D-4992-BA81-2FB741014088Q36534381-AC56FB60-671C-4901-A506-39A64EEBA375Q38631670-3A2FAA56-D1CB-4814-AF0C-2B61AAF0C7D6Q41265637-E060FF4F-EE83-45FC-BE5F-0AF614608221Q41842805-8EE91179-E19F-4625-AB61-59F803B30E52Q44400274-0B822F5A-9CD5-4181-B63C-2A41B3C6E0D9Q45085227-021EBF01-C145-46A4-9EDC-F9AC5496FA90Q49603020-AA4CEA77-43F9-4132-84C7-F118ABC3784D
P2860
Treatment with NS3623, a novel Cl-conductance blocker, ameliorates erythrocyte dehydration in transgenic SAD mice: a possible new therapeutic approach for sickle cell disease.
description
2001 nî lūn-bûn
@nan
2001 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մարտին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Treatment with NS3623, a novel ...... roach for sickle cell disease.
@ast
Treatment with NS3623, a novel ...... roach for sickle cell disease.
@en
type
label
Treatment with NS3623, a novel ...... roach for sickle cell disease.
@ast
Treatment with NS3623, a novel ...... roach for sickle cell disease.
@en
prefLabel
Treatment with NS3623, a novel ...... roach for sickle cell disease.
@ast
Treatment with NS3623, a novel ...... roach for sickle cell disease.
@en
P2093
P356
P1433
P1476
Treatment with NS3623, a novel ...... roach for sickle cell disease.
@en
P2093
Bennekou P
Brugnara C
Christophersen P
Pedersen O
de Franceschi L
P304
P356
10.1182/BLOOD.V97.5.1451
P407
P577
2001-03-01T00:00:00Z